Navigation Links
First targeted and programmable nanomedicine to show clinical antitumor effects published
Date:4/4/2012

Cambridge, MA, April 4, 2012 BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, that are capable of up to a ten-fold increase in drug concentration at tumor sites, has published preclinical and clinical data in Science Translational Medicine showing promising effects in solid tumors and successful clinical translation of BIND-014, the first targeted and programmed nanomedicine to enter human clinical studies.

In the paper titled "Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile," BIND scientists describe BIND-014's ability to concentrate in tumors and provide preclinical and clinical data demonstrating efficacy, safety and pharmacological properties that are superior to and highly differentiated from the parent chemotherapeutic drug, docetaxel. BIND-014 is the first clinical-stage targeted therapeutic nanoparticle with programmable pharmacological properties, including particle circulation time, pharmacokinetic profile, biodistribution and release profile. BIND-014 has been shown to effectively target a receptor expressed in tumors to achieve high drug concentrations at the site of disease.

"These seminal data on BIND's first clinical stage Accurin, BIND-014, demonstrates for the first time that it is possible to generate medicines with both targeted and programmable properties that can concentrate the therapeutic effect directly at the site of disease, potentially revolutionizing how complex diseases such as cancer are treated," commented Omid Farokhzad, M.D, BIND Founder and Associate Professor, Harvard Medical School. "BIND's data are a giant leap forward in achieving the true promise of nanomedicine by enabling the design of therapeutics with highly-differentiated efficacy and safety that go above and beyond the capabilities of traditional drug
'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
914-204-6412
The Yates Network
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. MiMedx Exceeds Revenue Goal for First Quarter of 2012
2. FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo
3. Expanded Findings for FirstMarks Completed Clinical Study for Predicting Near-Term (2-3 Years) MI
4. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
5. Researchers capture first-ever images of atoms moving in a molecule
6. Be One of the First to Experience Medtrack One View at the AUTM 2012 Annual Meeting
7. First Statewide Biotech Meeting Focuses on Patient Access, Innovation
8. Inaugural Meeting of the FirstMark Scientific Board of Advisors
9. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
10. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
11. Penn researchers build first physical metatronic circuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 ... that it will be participating in the Jefferies 2015 ... on Tuesday, June 2, 2015. Jeff ... question and answer session at 10:00 a.m. ET (3:00 ... be available on the Presentations and Webcasts section of ...
(Date:6/1/2015)... 29, 2015 Research and Markets( ... the "2015 Assessments of Leading Microbiology ... Recent Market Entrants" report to their ... from VPGMarketResearch.com provides insightful profiles of leading ... The report presents strategic assessments, ...
(Date:5/31/2015)... BARCELONA, Spain , June 1, 2015 /PRNewswire/ ... company dedicated to rare diseases, has selected Veeva ... across sales, marketing, and medical. A complete solution, ... data, multichannel interactions, and compliant content to provide ... and effective commercial execution.      (Logo: ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 The ... novel research for bile duct cancer, announced today ... Research Fellowship Program. , The Foundation ... scientists throughout the country to raise awareness about ... will support research that opens new pathways for ...
Breaking Biology Technology:Assessments of Leading Microbiology Market Players 2015 - Profiles of Major Suppliers and Recent Market Entrants 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 3The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3
... year,s first , quarter , - Total revenue of ... million , - Earnings per share of $0.29, an increase of ... - New products launched containing life,sDHA(TM) in a variety of , ... demonstrate the strong , leverage in our businessCOLUMBIA, Md., ...
... MOUNTAIN VIEW, Calif., March 4 The Healthcare ... pleased to announce its 2009 Quarterly Analyst Briefing ... be held on Thursday, March 5, 2009 at ... industry has witnessed healthy growth and is experiencing ...
... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" ... fourth quarter of 2008 was $334,041 compared to $174,071 for ... from the sale of PCT products and services was $233,256 ... $118,703 for the same period in 2007, a 97% increase. ...
Cached Biology Technology:Martek Announces First Quarter 2009 Financial Results 2Martek Announces First Quarter 2009 Financial Results 3Martek Announces First Quarter 2009 Financial Results 4Martek Announces First Quarter 2009 Financial Results 5Martek Announces First Quarter 2009 Financial Results 6Martek Announces First Quarter 2009 Financial Results 7Martek Announces First Quarter 2009 Financial Results 8Martek Announces First Quarter 2009 Financial Results 9Martek Announces First Quarter 2009 Financial Results 10Frost & Sullivan's Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells 2Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 2Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 3Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 4Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 5Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 6Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 7Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008 8
(Date:4/20/2015)... 2015 Huntington Memorial Hospital is the first ... new miniaturized, wireless monitoring sensor to manage heart failure ... only FDA-approved heart failure monitoring device that has been ... physicians to manage heart failure. The CardioMEMS ... the pulmonary artery (PA) during a non-surgical procedure to ...
(Date:4/17/2015)... April 17, 2015 ... and technological advancement to drive biometric systems market ... 2020   According to a recently ... Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... register growth at CAGR of over 22% through ...
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... Feb. 1, 2008) This months issue of ... methods to understand developmental processes in plants and flies. ... on the Web site for Cold Spring Harbor Protocols ... use of RNAi to investigate gene function in fruit flies. ...
... the role of a gene important to the embryonic ... coordination of differentiation of immature neural cells with the ... now, the mechanisms regulating these distinct cellular activities have ... published in the Feb. 15 issue of Development. ...
... Scientists at the University of Alabama at Birmingham ... uncover new details about the infectious potency of poxviruses, ... infections can subvert the bodys immune system. Having ... the discovery of new drugs to combat inflammation and ...
Cached Biology News:RNA-based methods for developmental studies are featured in Cold Spring Harbor Protocols 2Trainor Lab characterizes gene essential for prenatal development of nervous system 2Poxvirus potency uncovered in new atomic map 2
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
...
Anti-human Carcinoma Associated Antigen, Clone 115D8, Monoclonal Antibody Innate Immunity - Tumor Markers...
Rabbit polyclonal to Survivin DEx3 ( Abpromise for all tested applications). entrezGeneID: 332 SwissProtID: O15392...
Biology Products: